Alcon(ALC)
FORT WORTH, TX
Biotechnology1 H-1B visas (FY2023)Focus: Eye-Care Products
Alcon is a life sciences company focused on Eye-Care Products.
OphthalmologyCardiovascularInfectious DiseasesRespiratory
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (23)
27 discontinued products not shown
ALCAINE
proparacaine hydrochloride
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY Proparacaine hydrochloride ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.
1971
30
BETADINE
povidone-iodine
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY: A placebo-controlled study in 38 normal volunteers yielded data for 36 subjects who showed a mean log10 reduction of 3.05 log10 units in total aerobes at 10 minutes following prepping the skin with BETADINE* 5% Sterile Ophthalmic Prep Solution compared with reduction of 1.58 log10 units after prepping with vehicle free of the iodine complex. This placebo-controlled study indicates a mean log10 reduction by the iodine complex compared with the control solution of 1.47 log10 units at 10 minutes and 1.79 log10 units at 45 minutes. The base-line mean aerobic bacterial count was 7,586 organisms/cm2.
1986
30
BRIMONIDINE TARTRATE; TIMOLOL MALEATE
brimonidine tartrate; timolol maleate
Pre-Launch
OPHTHALMIC · SOLUTION
tartrate/timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. Brimonidine tartrate/timolol maleate ophthalmic solution is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate is a beta 1 and beta 2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.
elevated intraocular pressure (IOP) in patients with glaucomaocular hypertensionreplacement therapy due to inadequately controlled IOP+2 more
BSS
balanced salt solution
LOE Approaching
IRRIGATION · SOLUTION
CLINICAL PHARMACOLOGY: BSS Sterile Irrigating Solution is an isotonic solution for use in irrigating tissues of the eyes.
1997
30
BSS PLUS
balanced salt solution enriched with bicarbonate, dextrose, and glutathione
LOE Approaching
IRRIGATION · SOLUTION
CLINICAL PHARMACOLOGY None of the components of BSS PLUS are foreign to the eye. Human perfused cornea studies have shown BSS PLUS to be an effective irrigation solution for providing corneal detumescence and maintaining corneal endothelial integrity during intraocular perfusion. An in vivo study in rabbits has shown that BSS PLUS is more suitable than normal saline or Balanced Salt Solution for intravitreal irrigation because BSS PLUS contains the appropriate bicarbonate, pH, and ionic composition necessary for the maintenance of normal retinal electrical activity. Human in vivo studies have demonstrated BSS PLUS to be safe and effective when used during surgical procedures such as pars plana vitrectomy, phacoemulsification, cataract extraction/lens aspiration, anterior segment reconstruction. No differences have been observed between adults and pediatric patients following use of this drug product.
1981
30
CYCLOGYL
cyclopentolate hydrochloride
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
1974
30
CYCLOGYL
cyclopentolate hydrochloride
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY: This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
1974
30
CYCLOGYL
cyclopentolate hydrochloride
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY: This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
1974
30
CYCLOMYDRIL
cyclopentolate hydrochloride and phenylephrine hydrochloride
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY Cyclopentolate hydrochloride is an anticholinergic drug and phenylephrine hydrochloride is an adrenergic drug. This combination induces mydriasis that is greater than that of either drug alone at its respective concentration. The concentrations of cyclopentolate hydrochloride and phenylephrine hydrochloride have been selected to induce mydriasis with little accompanying cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.
1975
30
EYSUVIS
loteprednol etabonate
Peak
OPHTHALMIC · SUSPENSION/DROPS
healing. Corticosteroids inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. However, corticosteroids are thought to inhibit prostaglandin production.
2020
0
FLUORESCITE
fluorescein sodium
LOE Approaching
INTRAVENOUS · INJECTABLE
12.1 Mechanism of Action Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures. 12.3 Pharmacokinetics Distribution: Within 7 to 14 seconds after intravenous (IV) administration into antecubital vein, fluorescein usually appears in the central artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade after 6 to 12 hours of dosing. Various estimates of volume of distribution indicate that fluorescein distributes well into interstitial space (0.5 L/kg). Metabolism: Fluorescein undergoes rapid metabolism to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose, indicating relatively rapid conjugation. Excretion: Fluorescein and its metabolites are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.
diagnostic fluorescein angiographyangioscopy of the retinairis vasculature
2006
30
INVELTYS
loteprednol etabonate
Peak
OPHTHALMIC · SUSPENSION/DROPS
healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. However, corticosteroids are thought to inhibit prostaglandin production through several independent mechanisms.
post-operative inflammationpain following ocular surgery
2018
0
Pipeline & Clinical Trials
Contact lens correction of aphakia
Congenital CataractTravatan
Open Angle GlaucomaClinical Trials (1)
NCT00121147Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan
N/APerimetry
Primary Open Angle Glaucoma (POAG)Clinical Trials (1)
NCT00902109Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients
N/A3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix
PresbyopiaSystane® Ultra
Dry EyeClinical Trials (1)
NCT00946777Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days
N/ASN6AT6 Intraocular Lens
CataractsClinical Trials (1)
NCT01601665Post Approval Study of the AcrySof® IQ Toric Intraocular Lens (IOL) Models SN6AT6-SN6AT9
N/ASystane Complete
Dry Eye SyndromesClinical Trials (1)
NCT03706443Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops
N/ANelfilcon A toric contact lenses
MyopiaClinical Trials (1)
NCT01461811Prospective Study of an Investigational Toric Soft Contact Lens
N/AClareon Vivity Extended Vision IOL
AstigmatismClinical Trials (1)
NCT06784063Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs)
N/AOTF Ocular Lubricant
Dry EyeClinical Trials (1)
NCT05741216Evaluation of Comfort of Ocular Lubricants in Symptomatic Contact Lens Wearers
N/ALotrafilcon A contact lenses
Bullous KeratopathyClinical Trials (1)
NCT05956535Air Optix® Night and Day® Aqua Therapeutic Wear
N/ALotrafilcon B contact lens with color
MyopiaClinical Trials (1)
NCT01635933A Comparison of AIR OPTIX® COLORS Versus FRESHLOOK® COLORBLENDS
N/AUnity DX and SMARTCataract DX
CataractClinical Trials (1)
NCT06987474Capella Scientia Development Study
N/ALehfilcon A contact lens
Refractive ErrorsClinical Trials (1)
NCT04403542Pilot Clinical Performance of a Silicone Hydrogel Lens for Up to Six Nights of Extended Wear
N/AAssessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Dise
Sjogren's SyndromeClinical Trials (1)
NCT00809003Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
N/ADelefilcon A contact lenses
MyopiaClinical Trials (1)
NCT01561560Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses
N/ACiprofloxacin 0.3% and dexamethasone 0.1% otic suspension
Acute Otitis MediaClinical Trials (1)
NCT01027494Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora
N/ASystane
Dry EyeClinical Trials (1)
NCT01160133To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops
N/ASystane Ultra
Dry Eye DiseaseClinical Trials (1)
NCT01775540Systane Ultra Versus Maxidex Versus Saline
N/ADelfilcon A
Dry EyeClinical Trials (1)
NCT04105842Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
N/ADT1 Sphere Contact Lenses
Dry EyeClinical Trials (1)
NCT05239494Dailies Total 1 Sphere Contact Lenses
N/ALehfilcon A contact lenses
MyopiaClinical Trials (1)
NCT04980456Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses
N/APropylene glycol-based eye drops
Dry Eye DiseaseClinical Trials (1)
NCT03492541Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease
N/ANelfilcon A multifocal contact lens with comfort additive
MyopiaClinical Trials (1)
NCT01797783Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
N/ALotrafilcon B contact lens
AstigmatismClinical Trials (1)
NCT01007812Clinical Comparison of Two Silicone Hydrogel Toric Lenses in the US
N/AVerofilcon A toric soft contact lenses
AstigmatismClinical Trials (1)
NCT05483127Clinical Comparison of Two Daily Disposable Toric Soft Contact Lenses
N/APrecision1® Daily Disposable Contact Lens
Contact LensClinical Trials (1)
NCT05096156Evaluation of Wear Experience With Daily Contact Lenses
N/AReSTOR
CataractClinical Trials (1)
NCT00733512Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)
N/AVerofilcon A spherical soft contact lenses
Refractive ErrorsClinical Trials (1)
NCT06462456Post-market Clinical Follow-up Study of Alcon PRECISION1™ Spherical and PRECISION1™ for Astigmatism Soft Contact Lenses
N/AManifest refraction
CataractClinical Trials (1)
NCT02842151Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
N/ABlood Collection Only
Open-Angle GlaucomaClinical Trials (1)
NCT00691639Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)
N/ASYSTANE® Lid Wipes
Dry Eye SyndromeClinical Trials (1)
NCT01733745SYSTANE® Family - Meibomian Deficiency
N/Averofilcon A contact lenses
MyopiaClinical Trials (1)
NCT03305770DD T2 Daily Disposable Registration Trial
N/ADelefilcon A contact lenses
Refractive ErrorsClinical Trials (1)
NCT05010512Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
N/AClareon Vivity IOL - Non Toric
AphakiaClinical Trials (1)
NCT05796453Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
N/ATopography Guided LASIK Surgery
MyopiaClinical Trials (1)
NCT05611294Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction
N/ANGENUITY
GlaucomaClinical Trials (1)
NCT05529966Comparing NGENUITY vs Conventional Microscope in a New Hydrus User
N/ASYSTANE® ULTRA Lubricant Eye Drops
Dry Eye SyndromeClinical Trials (1)
NCT02446015Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye
N/ATOTAL30 for Astigmatism Contact Lenses
Contact Lens ComplicationClinical Trials (1)
NCT06052046Total30 for Astigmatism Contact Lenses
N/AOptiFree Multi-Purpose Disinfecting Solution
Contact Lens CareClinical Trials (1)
NCT00382603Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Soft Contact Lenses in Symptomatic Patients
N/AVerofilcon A contact lenses
Refractive ErrorsClinical Trials (1)
NCT05138783Clinical Performance of Two Daily Disposable Soft Contact Lenses
N/ALotrafilcon B contact lens with color
Cosmetic AppearanceClinical Trials (1)
NCT01398787Evaluation of the Cosmetic Performance of AIR OPTIX® COLORS
N/ACenturion® Vision System, 45° Balanced Tip
CataractsClinical Trials (1)
NCT02502526Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses
N/AFID123440 test formulation
Dry Eye DiseaseClinical Trials (1)
NCT07238699An Evaluation of the Safety and Tolerability of Ocular Lubricants
N/AHydrogen peroxide-based contact lens solution
Refractive ErrorClinical Trials (1)
NCT01996709Effectiveness of a Marketed One-Step Peroxide Lens Care Solution in Symptomatic Contact Lens Wearers
N/ADelefilcon A contact lenses
MyopiaClinical Trials (1)
NCT03628599Two Daily Disposable Contact Lenses in Symptomatic Patients
N/AStenfilcon A contact lenses
Refractive ErrorClinical Trials (1)
NCT02388763Clinical Evaluation of MyDay™ and 1-DAY ACUVUE® TruEye®
N/ALotrafilcon B contact lenses
MyopiaClinical Trials (1)
NCT01629693Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
N/ADelefilcon A spherical contact lens with molded marks
Refractive ErrorClinical Trials (1)
NCT02055404On-Eye Evaluation of Contact Lens Rotation Marks
N/ADelefilcon A contact lenses
Refractive ErrorClinical Trials (1)
NCT02072980DAILIES TOTAL1® Lubricity Post Wear
N/AOpen Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 60 approved products, 148 clinical trials
Top TAs: Ophthalmology, Cardiovascular, Infectious Diseases
H-1B (2023): 1 approval
Portfolio Health
Pre-Launch2 (3%)
Launch1 (2%)
Peak9 (15%)
LOE Approaching21 (35%)
Post-LOE27 (45%)
60 total products
Therapeutic Area Focus
Ophthalmology
4 marketed245 pipeline
Cardiovascular
2 marketed65 pipeline
Infectious Diseases
1 marketed
Respiratory
1 marketed
Marketed
Pipeline
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub